THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELAR
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.
Mentice AB (publ) ("Mentice" or the "Company") has received an additional subscription commitment of MSEK 3.4 in the Company’s rights issue announced on July 24, 2025 (the "Rights Issue").
In addition to previously entered subscription commitments, an existing shareholder has committed to subscribing for shares amounting to approximately MSEK 3.4, corresponding to about 10.6 percent of the Rights Issue. The subscription commitment is made on the same terms as for other investors, i.e., without compensation.
After the additional subscription commitment, the total amount of entered subscription commitments amounts to approximately 27.85 MSEK, corresponding to approximately 87.2 percent of the total amount of the Rights Issue of approximately 32.9 MSEK.
Advisors
Zonda Partners AB has been appointed as Sole Manager and Bookrunner in connection with the Rights Issue. Setterwalls Advokatbyrå AB is acting as legal advisor to the Company in connection with the Rights Issue.
To always stay on top within the field of medical simulation and its development subscribe to our news and resource list
More from Mentice